For three independent experiments. Symbols indicate significant differences between control-untreated and

For three independent experiments. Symbols indicate significant differences between control-untreated and treated cells (*p,0.01). doi:10.1371/journal.pone.0055203.g346 (low density lipoprotein receptor-related protein 6), Western blotting in our hands GSK429286A provided no signal and they were not further analyzed. Figures 3B and 3C show typical results obtained by Western blotting and the quantification of three independent experiments, respectively, for the rest of the marked proteins 131 (ELTD1), 133 (FADD), 234 (interleukin 1a) and 370 (MMP-1). The decrease in the levels of FADD detected in the array assays could 1531364 not be confirmed by Western blotting. On the contrary, the effects on the other three proteins could 23115181 be confirmed. In fact, as Figures 3B and 3C clearly show, get GSK429286A aeroplysinin-1 treatment (10 mM for 16 h) of SLIGKV-NH2 peptide-stimulated HUVEC produces decreases in the protein expression levels of ELTD1, MMP-1 and IL-1 a in their conditioned media.Aeroplysinin-1 Treatment Inhibits Cyclooxygenase-2 Expression in HUVECSince all the previous data clearly stressed the potential of the anti-angiogenic compound aeroplysinin-1 as an anti-inflammatory agent, we wanted to test whether it could down-regulate some other key pro-inflammatory gene not contained in the commercial arrays used. We decided to study COX-2, which is overexpressed in many tumors and plays a key role in atherosclerosis [16?8]. Constitutive expression of COX-2 is undetectable in HUVEC. However, COX-2 messenger and protein expression levels in HUVEC are easily induced by phorbol myristate acetate (PMA). Quantitative RT-PCR assay shows that aeroplysinin-1 treatment (10 mM for 4.5 h) decreased the expression levels of PMA (50 ng/Aeroplysinin-1 Inhibits Pro-Inflammatory MoleculesFigure 2. Aeroplysinin-1 decreases the expression levels of MCP-1 and TSP-1 in HUVEC. A) A typical result with GE-Array Q Series Human Angiogenesis Gene Array (SuperArray) is shown. B and C) Validation of the effects of aeroplysinin-1 on the expression levels of MCP-1. MCP-1 messengers were detected by semi-quantitative RT-PCR, using the levels of amplification of GAPDH as a control (B). MCP-1 protein was quantitatively determined by using an ELISA (C). D) Validation of the effects of aeroplysinin-1 on the expression levels of TSP-1. TSP-1 protein levels were detected by Western blotting, using the levels of b-actin as a control. Experiments were carried out as described in the Experimental Section. doi:10.1371/journal.pone.0055203.gmL)-induced COX-2 mRNA by more than 70 (Figure 4A). On the other hand, Western blot assays show that aeroplysinin-1 treatment (10 mM for 4.5 h) completely inhibited PMA-induced expression of endothelial cell COX-2 protein (Figure 4B). Therefore, aeroplysinin-1 seems to have inhibitory effects on PMA-induced expression of COX-2 protein that may involve effects at the transcriptional and post-transcriptional levels. The effect of aeroplysinin-1 on COX-2 protein expression levels was also shown in experiments with cycloheximide (90 mg/mL) pretreatment for 1 h (Figures 4C and D).DiscussionOur group demonstrated unambiguously that aeroplysinin-1, a brominated compound produced by marine sponges as a mechanism of defense [3,4], is a potent natural inhibitor of angiogenesis [12]. In that study, most of the in vitro experiments were carried out using bovine aorta endothelial cells (BAEC). As mentioned in the Introduction, BAEC are very frequently used as model cell cultures for ang.For three independent experiments. Symbols indicate significant differences between control-untreated and treated cells (*p,0.01). doi:10.1371/journal.pone.0055203.g346 (low density lipoprotein receptor-related protein 6), Western blotting in our hands provided no signal and they were not further analyzed. Figures 3B and 3C show typical results obtained by Western blotting and the quantification of three independent experiments, respectively, for the rest of the marked proteins 131 (ELTD1), 133 (FADD), 234 (interleukin 1a) and 370 (MMP-1). The decrease in the levels of FADD detected in the array assays could 1531364 not be confirmed by Western blotting. On the contrary, the effects on the other three proteins could 23115181 be confirmed. In fact, as Figures 3B and 3C clearly show, aeroplysinin-1 treatment (10 mM for 16 h) of SLIGKV-NH2 peptide-stimulated HUVEC produces decreases in the protein expression levels of ELTD1, MMP-1 and IL-1 a in their conditioned media.Aeroplysinin-1 Treatment Inhibits Cyclooxygenase-2 Expression in HUVECSince all the previous data clearly stressed the potential of the anti-angiogenic compound aeroplysinin-1 as an anti-inflammatory agent, we wanted to test whether it could down-regulate some other key pro-inflammatory gene not contained in the commercial arrays used. We decided to study COX-2, which is overexpressed in many tumors and plays a key role in atherosclerosis [16?8]. Constitutive expression of COX-2 is undetectable in HUVEC. However, COX-2 messenger and protein expression levels in HUVEC are easily induced by phorbol myristate acetate (PMA). Quantitative RT-PCR assay shows that aeroplysinin-1 treatment (10 mM for 4.5 h) decreased the expression levels of PMA (50 ng/Aeroplysinin-1 Inhibits Pro-Inflammatory MoleculesFigure 2. Aeroplysinin-1 decreases the expression levels of MCP-1 and TSP-1 in HUVEC. A) A typical result with GE-Array Q Series Human Angiogenesis Gene Array (SuperArray) is shown. B and C) Validation of the effects of aeroplysinin-1 on the expression levels of MCP-1. MCP-1 messengers were detected by semi-quantitative RT-PCR, using the levels of amplification of GAPDH as a control (B). MCP-1 protein was quantitatively determined by using an ELISA (C). D) Validation of the effects of aeroplysinin-1 on the expression levels of TSP-1. TSP-1 protein levels were detected by Western blotting, using the levels of b-actin as a control. Experiments were carried out as described in the Experimental Section. doi:10.1371/journal.pone.0055203.gmL)-induced COX-2 mRNA by more than 70 (Figure 4A). On the other hand, Western blot assays show that aeroplysinin-1 treatment (10 mM for 4.5 h) completely inhibited PMA-induced expression of endothelial cell COX-2 protein (Figure 4B). Therefore, aeroplysinin-1 seems to have inhibitory effects on PMA-induced expression of COX-2 protein that may involve effects at the transcriptional and post-transcriptional levels. The effect of aeroplysinin-1 on COX-2 protein expression levels was also shown in experiments with cycloheximide (90 mg/mL) pretreatment for 1 h (Figures 4C and D).DiscussionOur group demonstrated unambiguously that aeroplysinin-1, a brominated compound produced by marine sponges as a mechanism of defense [3,4], is a potent natural inhibitor of angiogenesis [12]. In that study, most of the in vitro experiments were carried out using bovine aorta endothelial cells (BAEC). As mentioned in the Introduction, BAEC are very frequently used as model cell cultures for ang.